Best of ASCO - 2014 Annual Meeting

 

Welcome

Biomarkers/Epidemiology/Outcomes

Head and Neck Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A radiomics signature for treatment stratification in advanced and recurrent nasopharynx cancer.

Grace Kusumawidjaja

e18060

A study to evaluate immunological response to PD-1 inhibition in squamous cell carcinoma of the head and neck (SCCHN) using novel PET imaging with [18F]F-AraG.

A. Dimitrios Colevas

6050

Absolute lymphocyte count (ALC) during and after chemoradiation (CRT) for squamous cell carcinoma of the head and neck (SCCHN): Effect of the regimen and potential therapeutic implications.

Marit Uglane

6042

Are signatures of radiosensitivity ready for routine clinical use? A pragmatic comparison of clinical, pathological, and gene signature predictors of outcome in oropharynx head and neck cancers.

Andrew Dhawan

e18046

Association of low serum albumin concentration with reduced overall survival for patients with metastatic head and neck cancer receiving anti-programmed death receptor-1 therapy.

Sara Kochanny

6057

Cardiovascular disease risks among head and neck cancer survivors in a large, population-based cohort study.

Mei Wei

6051

Cisplatin dose intensity (CDDP-D) in human papillomavirus-positive (HPV+) localized oropharyngeal carcinoma (OPC) treated with chemoradiotherapy (CRT).

Marc Oliva Bernal

6044

Cisplatin-induced ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with chemoradiation: The role of WFS1 and ABCC2 heritable variants.

Mary Mahler

6048

Comprehensive proteomic and genomic profiling to identify therapeutic targets in adenoid cystic carcinoma.

Sheeno P. Thyparambil

6053

Development and validation of a combined metabolic and immune prognostic classifier for head and neck cancer.

Hisham Mohamed Mehanna

6049

Discovery of a reliable and robust methylome classifier of HPV driven head and neck cancer with favorable response to chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).

Bouchra Tawk

6019

Epidemiological trends of head and neck cancer survivors in Alberta: Towards improved understanding of the burden of disease.

Patrick Vallance

e18052

Gene expression signature after one dose of neoadjuvant pembrolizumab associated with tumor response in head and neck squamous cell carcinoma (HNSCC).

Eejung Kim

6059

Head and neck cancer in octogenarians: A single center experience.

Parth Anil Desai

e18044

High-accuracy HPV testing versus p16 IHC using multiple clinically relevant outcomes: The University of Chicago Experience.

Sara Kochanny

6020

ICR gene signature to identify differential immune landscapes in anatomic subsites of head and neck squamous cell carcinomas and implications in personalized medicine.

Sara I. Pai

6052

Immune profiling of head and neck squamous cell carcinoma (HNSCC) by a multiplex immunofluorescence (mIF) panel using multispectral microscopy.

Janis De La Iglesia

6061

Impacts of plasma EBV DNA load during different time-points of induction chemotherapy plus radiotherapy for nasopharyngeal carcinoma.

Jin-Ching Lin

6058

Incidence of ototoxicity in head and neck cancer (HNSCC) patients (pts) receiving concomitant chemo-radiation (CRT) with weekly or triweekly cisplatin (Cis).

Jishu Das

6046

Interference between mutational load, immune signatures and outcome in patients with head and neck cancer treated with definitive chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).

Inge Tinhofer

6047

Is marital status as impactful as chemotherapy among patients with head and neck cancer?

Nosayaba Osazuwa-Peters

e18058

Mechanism of acquired resistance to cetuximab in head and neck cancer.

Arun Khattri

e18061

Minimally-invasive dual testing for active HPV E6,E7 and PD-L1 expression in HNSCC.

Haitham Mirghani

6064

Molecular prediction of lymph node metastases using immunohistochemical analysis of primary oral tongue squamous cell carcinomas.

Furrat Amen

6054

Number of nodal metastases associated with overall survival in HPV-negative head and neck cancer.

Doug Farquhar

6062

PATHOS: A phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for human papillomavirus (HPV)-positive oropharyngeal cancer.

Mererid Evans

TPS6097

Plasma levels of soluble programmed death ligand 1 (sPD-L1) and its clincial value in patients with nasopharyngeal carcinoma (NPC): A preliminary study.

Man Hu

e18048

Post-transplant head and neck cancers: A prospective analysis of clinical factors for risk stratification.

Joanne Soo

e18051

Predicting unreported clinical trial efficacy using an ex-vivo tumor platform: Pembrolizumab+pt+5-FU vs. extreme in recurrent head and neck squamous cell carcinoma.

Munisha Smalley

e18042

Prognostic and predictive value of HPV status in metastatic squamous cell carcinoma of the head and neck.

Luke Roy George Pike

e18038

Prognostic role of inflammatory index in head and neck squamous-cell carcinoma patients in first line chemotherapy.

Valentina Fausti

e18054

Prognostic role of pretreatment plasma EBV DNA on stage III nasopharyngeal carcinoma staged by AJCC/UICC 8th edition TNM staging classification.

Victor Lee

6055

Prognostic significance of automated score of tumor infiltrating lymphocytes in oral cancer.

Muhammad Shaban

e18036

Psychological distress before and after surgical resection of orofacial tumours.

Azeez Fashina

e18043

Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

Kevin J. Harrington

6045

Relationship of low stathmin expression and benefit from TPF induction chemotherapy and its role in chemoresistance via mutant p53 in oral cancer.

Lai-Ping Zhong

e18034

Role of ERBB receptor feedback inhibitor 1 (ERRFI1) downregulation in progression of premalignant oral lesions to cancer.

Prajwal A

e18045

Role of hematologic markers as prognostic factors in head and neck squamous cell carcinoma: Experience of a Brazilian Public Hospital.

Tiago Costa de Padua

e18041

Second primary thyroid cancer following index head and neck cancer.

Katherine M. Polednik

6060

Should surveillance guidelines be different based on Human Papilloma Virus (HPV) status? Patterns of failure and second primary cancers (SPM) in patients (pts) with oropharyngeal squamous cell cancer (OPSCC).

Ryan Holstead

e18059

Smoking and human papillomavirus (HPV) as pronostic factors of oropharyngeal squamous cell carcinoma in the population of salamanca: Spain.

Roberto Escala

e18056

Survival outcomes by HPV status in non-oropharyngeal head and neck cancers: A propensity score matched analysis of population level data.

Sibo Tian

6005

The addition of chemotherapy to adjuvant therapy in patients with intermediate risk HNSCC may cause harm.

Siddharth Sheth

e18057

The use of exosome and immune profiling to analyze a phase 2 study on the addition of patritumab or placebo to cetuximab and a platinum agent for recurrent / metastatic head and neck cancer (R/M HNSCC) patients.

Tony Ng

6043

Tongue cancer patients can be distinguished from healthy controls by specific N-glycopeptides found in serum.

Suvi Renkonen

e18047

Tracking tumor-specific mutations in plasma, saliva and para-carcinoma tissues from patients with head and neck squamous cell carcinomas.

Ping Wu

6056

TREM-1 expression in HPV related oropharyngeal squamous cell carcinoma (OP-SCC).

Mario Airoldi

e18037

Type-specific data on human papillomavirus infection in squamous cell carcinomas of the head and neck across anatomic sites and world regions.

Liga Bennetts

e18055

Using mobile and sensor technology to identify early dehydration risk in head and neck cancer patients undergoing radiation treatment: Impact on symptoms.

Susan K. Peterson

6063